Published 2 years ago

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study - Alzamend Neuro (NASDAQ:ALZN)

Summary by Business Wire

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

0 Articles

All

Left

Center

Right

Benzinga

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study - Alzamend Neuro (NASDAQ:ALZN)

2 years ago·New York, United States

Read Full Article

Business Wire

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

2 years ago·Crystal River, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated2 years agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study - Alzamend Neuro (NASDAQ:ALZN)

0 Articles

0 Articles

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study - Alzamend Neuro (NASDAQ:ALZN)

Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study - Alzamend Neuro (NASDAQ:ALZN)

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics